BACKGROUND: Women diagnosed with lobular carcinoma in situ (LCIS) have a 3-fold to 10-fold increased risk of developing invasive breast cancer. The objective of this study was to evaluate the life expectancy (LE) and differences in survival offered by active surveillance, risk-reducing chemoprevention, and bilateral prophylactic mastectomy among women with LCIS. METHODS: A Markov simulation model was constructed to determine average LE and quality-adjusted LE (QALE) gains for hypothetical cohorts of women diagnosed with LCIS at various ages under alternative risk-reduction strategies. Probabilities for invasive breast cancer, breast cancer-specific mortality, other-cause mortality and the effectiveness of preventive strategies were derived from published studies and from the National Cancer Institute's Surveillance, Epidemiology, and End Results database. RESULTS: Assuming a breast cancer incidence from 1.02% to 1.37% per year under active surveillance, a woman aged 50 years diagnosed with LCIS would have a total LE of 32.78 years and would gain 0.13 years (1.6 months) in LE by adding chemoprevention and 0.25 years (3.0 months) in LE by adding bilateral prophylactic mastectomy. After quality adjustment, chemoprevention resulted in the greatest QALE for women ages 40 to 60 years at LCIS diagnosis, whereas surveillance remained the preferred strategy for optimizing QALE among women diagnosed at age 65 years and older. CONCLUSIONS: In this model, among women with a diagnosis of LCIS, breast cancer prevention strategies only modestly affected overall survival, whereas chemoprevention was modeled as the preferred management strategy for optimizing invasive disease-free survival while prolonging QALE form women younger than 65 years.
INTRODUCTION
Lobular carcinoma in situ (LCIS) is a clinically occult, high-risk lesion diagnosed as an incidental finding on 0.5% to 3.8% of all breast biopsies. 1, 2 Compared with the general population, women with LCIS have a 3-fold to 10-fold increased risk of invasive breast cancer, with an estimated annual rate of breast cancer of 1% to 2% across several studies. [3] [4] [5] [6] [7] In addition to being a marker of increased risk in both breasts, LCIS predisposes women to modestly higher rates of breast cancer in the ipsilateral breast, prompting some to suggest that LCIS may also represent a nonobligate precursor of ipsilateral invasive disease. [8] [9] [10] [11] With the widespread adoption of screening mammography and the increased performance of image-guided breast biopsies, the incidence of LCIS has steadily risen. 12, 13 Yet quantifying risk and tailoring management for the individual remains a challenge for physicians. Currently, National Comprehensive Cancer Network clinical practice guidelines recommend that, after undergoing surgical biopsy or wide local excision to exclude concordant malignancy, women with LCIS should continue surveillance with annual mammography and clinical breast examination every 6 to 12 months, with consideration of annual breast magnetic resonance imaging. 14 Other guidelines, including those from the American Cancer Society, contend that there is insufficient evidence to support the use of magnetic resonance imaging in women with LCIS yet support its use for women who have a >20% lifetime risk of developing breast cancer based on hereditary risk models, which adds to conflicting advice for women with LCIS. 15 In addition to active surveillance, women with LCIS may consider several preventative strategies, such as chemoprevention with modulating endocrine therapy or bilateral prophylactic mastectomy (BPM), to reduce their risk of a subsequent invasive cancer. Chemoprevention has proven effective at reducing the risk of developing breast cancer by >50% in prospective prevention trials, including patients with LCIS. 16, 17 For risk-reducing surgery, efficacy can be extrapolated from the literature on breast cancer gene (BRCA) carriers and other high-risk women, for whom the reduction in risk with BPM is >90%. 18, 19 Decisions regarding the best option for managing patients with LCIS are layered and complex. Despite the elevated risk, most women with LCIS will never be diagnosed with breast cancer; and, if they are diagnosed, few will die from their malignancy. In addition, there are side effects associated with chemoprevention as well as the surgical morbidity and quality-of-life reductions associated with a major operation like BPM, with or without reconstruction. To reconcile the differences between these risks and benefits, we constructed a decision-analytic model to evaluate differences in overall and quality-adjusted life expectancy (QALE) between the several management options offered to women with LCIS.
MATERIALS AND METHODS

Decision Analysis Model Design
We used TreeAgePro Software 2015 (TreeAge Software Inc, Williamstown, Mass) to construct a Markov cohort simulation model to determine average life expectancy and survival for different LCIS management strategies that aim to minimize the risk of invasive breast cancer. The model simulates the clinical history of theoretical cohorts of women with newly diagnosed, classic LCIS (lobular intraepithelial neoplasia 2) who, after surgical excision to exclude concordant malignancy and/or assurance of radiopathologic concordance before nonoperative management, are randomly allocated to 1 of the following management strategies: 1) standard active surveillance, 2) chemoprevention with 5 years of tamoxifen therapy, or 3) BPM.
Our model consisted of multiple, mutually exclusive health states (being well with history of LCIS, alive with history of invasive breast cancer, dead from breast cancer or other causes) through which an individual may transition annually according to a given set of transition probabilities (Fig. 1 ). Simulations were repeated for cohorts of women that varied in age at LCIS diagnosis, with agespecific incidence rates for the diagnosis of a subsequent invasive breast cancer incorporated into the model. For each cohort, we compared the amount of time spent in each health state and ran the model until all patients had died (either from breast cancer or competing risks of death) or were 100 years of age. The primary outcomes studied included gains in life expectancy and QALE for each of the strategies at the time of LCIS diagnosis. We also examined 10-year and 20-year invasive disease-free survival (DFS) and breast-cancer specific mortality estimates. Cycle length was modeled at 1 year, with a halfcycle correction applied.
Data Sources
The baseline data estimates and ranges included in the sensitivity analysis are provided in Table 1 .
16,19-28
Invasive Breast Cancer Incidence and Stage Distribution
We used the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database to identify women who had a histologically confirmed diagnosis of LCIS (International Classification of Diseases for Oncology, third edition, code 8520/2) between 1983 and 2013 as well as those who developed a subsequent invasive breast cancer a minimum of 6 months after their diagnosis of LCIS. The Kaplan-Meier method was then used to estimate 20-year age-specific cumulative incidence rates for the diagnosis of a subsequent breast malignancy. The derived American Joint Committee on Cancer sixth edition TNM stage distribution of women diagnosed with any (ipsilateral or contralateral) breast cancer subsequent to a diagnosis of LCIS was also generated from SEER data. 20 
Breast Cancer-Specific and Background Mortality
Ten-year stage-specific mortality rates according to the American Joint Committee on Cancer sixth edition TNM stage for all women diagnosed with a histologically confirmed stage I through IV breast cancer between 2003 and 2013 were obtained from SEER data. The Kaplan-Meier method was used to derive 10-year stagespecific survival estimates, which were then converted into mortality rates from which we calculated annual transition probabilities of death. We assumed that women who developed cancer after a diagnosis of LCIS carried the same prognosis as other patients with breast cancer within the same stage. The age-specific risk of death from other causes was obtained from US life-table estimates.
Original Article
Effectiveness of Risk-Reducing Strategies
Chemoprevention
The effectiveness of risk-reducing chemoprevention was derived from the National Surgical Adjuvant Breast and Bowel Project Prevention-1 study (NSABP P-1), which randomized 13,175 high-risk women to receive either tamoxifen therapy for 5 years or placebo. Overall, 6.3% of women in the NSABP P-1 trial had a history of LCIS, and subgroup analysis demonstrated a 56% risk reduction in breast cancer incidence among these women. 16 Documented complications from tamoxifen therapy expected to alter overall life expectancy were incorporated into the model in an age-dependent fashion. For the cohorts of women diagnosed with LCIS at ages 50 and 60 years, these effects included the increased risk of endometrial cancer and thromboembolic complications, such as pulmonary emboli. The incidence of these effects were obtained from the NSABP P-1 study and incorporated into our model for the 5-year duration of therapy. 16, 17 The reduced risk of hip fractures, the increased risk of cataracts, vasomotor symptoms, and vaginal discharge, and the negative effect on sexual functioning were modeled into the quality-adjusted analysis through reductions in mean preference ratings for the chemoprevention health state.
BPM
We based our estimates of the efficacy of preventive strategies on studies suggesting that BPM reduces the risk of breast cancer by 90% to 96%. 19, [21] [22] [23] [24] For our base-case estimates, we assumed that surgery reduced the annual risk of breast cancer by 90% and that the effect was life-long. Given the recognized safety of the procedure, 29 mortality secondary to surgery was excluded from the model.
Utility Values
The model accounted for health-related quality of life by assigning each unique health state a utility value on a scale from zero to 1, with zero representing death and 1 representing perfect health. Utility values describe preference ratings that individuals assign to specific conditions or outcomes in the context of uncertainty and are useful in clinical decision making and cost-effectiveness analyses by weighing quality of life against its remaining quantity. For the current study, all utility values were obtained from the literature, with the exception of being healthy with LCIS, for which no studies were available. [26] [27] [28] For utilities associated with breast cancer prevention strategies, we used values derived from Grann et al, who obtained mean patient-preference ratings using a time-tradeoff instrument on high-risk BRCA mutation carriers. 26 
Model Assumptions
We assumed that the risk of invasive breast cancer was age specific and remained constant from the year of LCIS diagnosis to the end of the patient's lifespan or until a diagnosis of invasive breast cancer was made. After they Figure 1 . This decision tree illustrates the model used in the current study. BPM, bilateral prophylactic mastectomy; Dx, diagnosis; LCIS, lobular carcinoma in situ; M, Markov cohort. An asterisk indicates that side effects were modeled for those who received chemoprevention according to age at diagnosis.
received a diagnosis of invasive breast cancer, women were assigned a stage-specific, cancer-related mortality for a period of 10 years. For women with stage I through III breast cancer, survival over the subsequent 10-year period was determined by stage-specific breast cancer mortality rates derived from the SEER database. After 10 years, the risk of death returned to the background mortality rate for women that age. Women with stage IV breast cancer remained in the metastatic health state until death.
We assumed that management strategy had no effect on the stage distribution of subsequent invasive breast cancers. For the effect of chemoprevention on our basecase estimates, we assumed that the 56% risk reduction would be stable annually for 15 years before returning to baseline. We assumed that the risk of experiencing a side effect from tamoxifen chemoprevention was confined to the 5-year treatment period, returning to baseline after the completion of tamoxifen therapy. Extrapolating from the findings in the NSABP P-1 trial, our model assumed that the majority of endometrial cancers secondary to tamoxifen were diagnosed as stage I, with an associated 5-year mortality rate of 5%. A 1-year mortality rate from pulmonary embolus of 15% was extracted from the literature. 25 
Sensitivity Analyses
Sensitivity analyses were performed to test the stability of results to changes in base-case parameter estimates. These variables included the effectiveness of both tamoxifen chemoprevention and BPM and the duration of the effect associated with chemoprevention. The probabilities used in base-case analysis and the ranges incorporated into the sensitivity analyses are listed in Table 1 .
RESULTS
Gains in Average Life Expectancy
The model results indicate that the addition of chemoprevention or BPM modestly increase life expectancy in women diagnosed with LCIS. Table 2 demonstrates the predicted average life expectancies and life expectancy gains according to each separate management strategy. On average, for women aged 50 years at the time of LCIS diagnosis, the remaining life expectancy was modeled as 32.78 years, with 0.13 years (1.6 months) gained through the use of chemoprevention and 0.25 years (3.0 months) gained through BPM.
The largest gains in life expectancy were observed in younger women with LCIS. For those aged 40 years at diagnosis, compared with active surveillance, the receipt of chemoprevention increased average life expectancy by 0.17 years (2.04 months), whereas risk-reducing surgery increased average life expectancy by 0.33 years (3.96 months). This contrasted with women who were diagnosed at age 65 years, for whom the benefits of chemoprevention and BPM were lower, increasing average life expectancy by only 0.09 years (1.08 months) and 0.15 years (1.8 months), respectively.
Gains in QALE
When life expectancy was quality adjusted, however, chemoprevention was associated with the largest gains in life expectancies for all cohorts up to age 60 years, with QALE Table 2) . Table 3 depicts the predicted absolute 10-year and 20-year OS and DFS differences according to each management strategy. Assuming age-specific annual incidence rates of breast cancer between 1.02% and 1.37%, the 10-year overall survival (OS) rate with active surveillance was 97.4% for women diagnosed at age 40 years, 94.9% for those diagnosed at age 50 years, and 89.6% or those diagnosed at age 60 years. Absolute percent differences in 10-year OS were modest, ranging from 0.3% to 0.4% with chemoprevention and from 0.5% to 0.7% with BPM. Contingent on age at diagnosis, 10-year DFS differences ranged from 5.2% to 6.3% with chemoprevention and from 8.4% to 10.4% with BPM. DFS was lower in older age groups, in which the incidence of breast cancer was higher and OS was lower. In the cohort diagnosed with LCIS at age 40 years, 88.5% of patients who underwent surveillance were alive with no invasive breast cancer at 10 years compared with 93.7% those who received chemoprevention and 97% of those who underwent BPM. This contrasted with cohort diagnosed at age 60 years, of which 78.6% were alive and disease free at 10 years compared with 84.9% and 89% in the chemoprevention and BPM arms, respectively.
Impact of Preventive Strategies on Overall Survival and DFS
Breast Cancer-Specific Mortality and Death From Other Causes
For women diagnosed with LCIS, our model demonstrated favorable 10-year and 20-year breast cancer-specific mortality rates, with the majority of women dying of other causes. In the cohort diagnosed at age 50 years, 20-year breast cancer-specific mortality was < 1% (range, 0.10%-0.99%) across all management strategies, whereas 13.5% of the cohort had died from other causes (Table 4) . In those diagnosed with LCIS at age 60 years, 20-year breast cancer-specific mortality again was low at 0.12% to month gain among those diagnosed at women age 60 years. These estimates remained fairly consistent (0.24-month to 0.48-month difference) with our base-case parameter results, whereas decreasing the effectiveness of chemoprevention from a 10% to 60% risk reduction changed life expectancy gains from 0.12 to 1.80 months in women diagnosed at age 40 years, 0.12 to 1.32 months in those diagnosed at age 50 years, and 0.08 to 0.12 months in those diagnosed at age 60 years. We assumed that treatment with tamoxifen resulted in a stable risk reduction over the course of therapy and a continued 10-year period after treatment cessation. Although increasing the duration of tamoxifen risk reduction for 5 additional years resulted in improved life expectancy in younger cohorts up to age 50 years, the results remained stable with no significant survival benefit beyond a 20-year duration of overall tamoxifen effect in those who were diagnosed with LCIS at age 60 years.
DISCUSSION
Compared with the general population, women diagnosed with LCIS have a 3-fold to 10-fold increased risk of breast cancer conferred in either breast. Several long-term studies have reported a cumulative risk of subsequent ductal carcinoma in situ or invasive malignancy ranging between 7.1% and 13% at 10 years and between 11% and 26% at 15 years, with the cumulative incidence of breast cancer remaining linear over time. 3, 4, 30 Beyond these estimates, there is little to inform clinical management decisions, because scarce data exist identifying the patient or prognostic factors that best predict which women with LCIS will go on to develop a subsequent malignancy. 31 Although conservative management with surgical excision and/or close clinical surveillance remain options and are the most common, women diagnosed with LCIS may perceive that their long-term absolute risk of breast cancer is unacceptably high given the length of their overall life expectancy. For these women, endocrine modulation and surgical risk reduction are 2 possible prevention strategies, and each is associated with its own risks and benefits.
The efficacy of chemoprevention has been well established through large, randomized, controlled trials performed over the last several decades, 17, [32] [33] [34] [35] [36] and subgroup analyses on data from women with LCIS are available from several of such trials. The NSABP P-1 trial demonstrated a risk reduction of nearly 56% in invasive breast cancer and ductal carcinoma in situ among patients with LCIS who received 5 years of tamoxifen compared with those who received placebo. 16, 17 Subsequently, the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial established equivalency between 5 years of raloxifene and the same duration of tamoxifen in postmenopausal women for reducing the risk of invasive carcinoma, demonstrating a more favorable side-effect profile in the raloxifene arm with respect to thromboembolic events and cataract formation. 35 In 2011, the Mammary Prevention 3 (MAP.3) trial reported a 53% relative reduction in the annual incidence of in situ and invasive breast cancers for high-risk women who were randomized to receive exemestane versus placebo with a median follow-up of 3 years 34 ; and in 2014, the IBIS-II trial (adjuvant tamoxifen compared with anastrozole in treatment postmenopausal women) published similar findings with the use of anastrozole. 36 Although the long-term effects of these agents remain under investigation, little is known regarding whether their use will translate into a survival benefit. Extended long-term results from the IBIS-I study reported no significant improvement in breast cancer-specific survival or OS in the tamoxifen arm despite a sustained risk reduction in in situ and invasive breast cancer at a median follow-up of 16 years (hazard ratio, 0.71; 95% confidence interval, 0.60-0.83). 32 Yet, because deaths from breast cancer in this high-risk population remain a rare event, such studies were not designed to detect such differences and, with the limited follow-up available, cannot yet inform women about their lifetime risk of dying from a subsequent breast cancer.
It has been demonstrated that BPM can significantly reduce the risk of breast cancer in high-risk women, in turn diminishing the need for close clinical follow-up and obviating the need for imaging surveillance. 18, 19, 21 In cohorts of women with LCIS, those who opt for BPM tend to be premenopausal, have mammographically dense breasts, and have a stronger family history relative to those who choose surveillance or chemoprevention. 30 However, although overall satisfaction with BPM is reportedly high, surveys of women who undergo bilateral surgery have indicated that up to one-third report negative physical effects, and a significant minority of respondents have a lessened sense of sexuality after surgery. [37] [38] [39] In addition, the length of recovery time can range from several months to years, with rates of unanticipated reoperation observed in up to 50%, particularly among women who undergo reconstruction. 40 In the absence of long-term data on outcomes with different management strategies, the risk-benefit calculation for women with newly diagnosed LCIS remains a challenge, particularly because most of these high-risk women will not be diagnosed with breast cancer, and those who are diagnosed carry a low overall mortality risk from their subsequent malignancy. Indeed, in our model of women with LCIS who were managed with surveillance alone, the lifetime risk of death from breast cancer was only 1.26% to 1.31%, depending on age at diagnosis (data not shown), with the overwhelming majority of women dying from noncancer-related causes.
Results from our model also suggest that, at an agespecific annual incidence of breast cancer ranging from 1.02% to 1.37%, preventive strategies very modestly increase OS and life expectancy compared with surveillance alone. Chemoprevention increased average life expectancy in women diagnosed with LCIS at ages 40 to 65 years by 1.1 to 2.04 months, respectively, whereas BPM resulted in gains of 1.8 to 3.96 months. These gains do not adjust for quality of life, nor do they take into account the length of recovery from bilateral surgery, which, if prolonged, may substantially offset the reported survival benefit.
When health-related quality of life is taken into account, BPM becomes the least favorable strategy, with losses of between 1.9 and 3.69 quality-adjusted life years. Younger women who undergo risk-reducing surgery experience the greatest losses in quality-adjusted life expectancy given their large number of remaining life years and the quality-of-life reductions associated with BPM incurred over this prolonged period. In contrast, after quality adjustment, our model indicated that chemoprevention was the preferred management strategy, resulting in the largest gains of QALE-between 0.6 and 2.52 months-for cohorts diagnosed with LCIS between ages 40 and 60 years. Beyond age 65 years, surveillance became the strategy associated with the greatest quality-adjusted survival.
Taken together, these data highlight the findings that breast cancer prevention strategies in LCIS will only modestly affect OS, whereas chemoprevention should remain the preferred management strategy for women aged <65 years who want to optimize invasive DFS while prolonging QALE. It is noteworthy that this is not reflected in current practice patterns, in which studies have demonstrated that chemoprevention uptake remains poor and that adherence to 5 years of therapy is difficult. [41] [42] [43] The current study has several limitations. First, we made several assumptions regarding the incidence of breast cancer in LCIS and the effects of current preventive strategies on its natural history. In reality, women with LCIS may present with several other risk factors for breast cancer, including a strong family history or dense breasts, which we did not incorporate into our model. In addition, although our assumptions regarding the effects of chemoprevention were drawn from results of the most recent relevant clinical trials, we did not explore pharmacologic agents aside from tamoxifen; and, in the absence of long-term data regarding the duration of its effect, we assumed that the effects of chemoprevention were finite. In addition, for determining the effectiveness of riskreducing surgery, we extrapolated from observational studies on high-risk BRCA carriers that may have underestimated the overall efficacy of this strategy for women with lower risk LCIS.
Despite the stated limitations, our results suggest that women with LCIS have a reduced risk of invasive breast cancer and prolonged QALE through the use of chemoprevention agents. Furthermore, regardless of management strategy, women with LCIS can expect to have a very low risk of mortality secondary to breast cancer. Our hope is that the modeled survival and quality-of-life outcomes reported in this study will help women estimate and compare the benefits across each preventive strategy and aid patients and providers in making these complex, preference-sensitive decisions. Future prospective research will be required to better determine which patients achieve the greatest possible benefit from surveillance, chemoprevention, or risk-reducing surgery.
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